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Abstract
This cross-sectional study of 3212 pregnant women assessed the field performance, acceptability, 
and feasibility of two dual HIV/syphilis rapid diagnostic tests, the Chembio DPP HIV-syphilis 
Assay and the SD Bioline HIV/syphilis Duo in antenatal clinics. Sensitivity and specificity for 
HIV and syphilis were calculated compared to the rapid Determine HIV-1/2 with Uni-Gold to 
confirm positive results for HIV and the Treponema pallidum particle agglutination assay for 
syphilis. RPR titers ≥1:4 were used to define active syphilis detection. Acceptability and feasibility 
were assessed using self-reported questionnaires. For Chembio, the HIV sensitivity was 90.6% 
(95%CI = 87.4, 93.0) and specificity was 97.2% (95%CI = 96.2, 97.8); syphilis sensitivity was 
68.6% (95%CI = 61.9, 74.6) and specificity was 98.5% (95%CI = 97.8, 98.9). For SD Bioline, 
HIV sensitivity was 89.4% (95%CI = 86.1, 92.0) and specificity was 96.3% (95%CI = 95.3, 97.1); 
syphilis sensitivity was 66.2% (95%CI = 59.4, 72.4) and specificity was 97.2% (95%CI = 96.4, 
97.9). Using the reference for active syphilis, syphilis sensitivity was 84.7% (95%CI = 76.1, 90.6) 
for Chembio and 81.6% (95%CI = 72.7, 88.1) for SD Bioline. Both rapid diagnostic tests were 
assessed as highly acceptable and feasible. In a field setting, the performance of both rapid 
diagnostic tests was comparable to other published field evaluations and each was rated highly 
acceptable and feasible. These findings can be used to guide further research and proposed scale 
up in antenatal clinic settings.
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Introduction
Mother-to-child transmission (MTCT) of HIV and syphilis remains a major global public 
health concern due to high associated infant morbidity and mortality.1 In 2014, an estimated 
1.2 million HIV-infected pregnant women gave birth to 170,000 infants with HIV in areas 
that account for 90% of the global burden.2 In 2012, an estimated 930,000 pregnant women 
were infected with syphilis resulting in 350,000 adverse birth outcomes, of which 
approximately half were stillbirths or neonatal deaths.3 In 2010, the Zambia HIV antenatal 
prevalence was estimated at 16.4%4 while syphilis prevalence was reported as 
approximately 9.0% in a study conducted among pregnant women attending antenatal clinics 
(ANCs) during 2009–2010.5
HIV and syphilis coinfection is common in Zambia, with an estimated 24.2% of syphilis-
positive pregnant women also testing HIV-positive.5 Observational studies suggest that 
infants born to pregnant women coinfected with HIV and syphilis have twice the risk of 
being HIV infected compared to infants of mothers infected with HIV alone.5,6 Early 
screening and prompt treatment of pregnant women for HIV and syphilis can reduce the risk 
of MTCT of both diseases and prevent adverse birth outcomes.7–9 Recognizing this benefit 
and in pursuit of dual elimination of MTCT of HIV and syphilis, the World Health 
Organization promotes improved diagnostic techniques such as rapid diagnostic tests 
(RDTs) for screening for sexually transmitted infections including HIV and syphilis during 
pregnancy in order to reduce barriers to testing and ensure receipt of results and prompt 
treatment.5
In this study we evaluated the field performance, acceptability, and feasibility of two dual 
tests, the SD BIOLINE HIV/Syphilis Duo Test (Standard Diagnostics, Korea) and the 
Chembio Dual Path Platform (DPP®)10,11 HIV-Syphilis Assay (Medford, NY, USA) among 
pregnant women seeking antenatal care in Lusaka, Zambia.
Methods
Study design and setting
This field evaluation was conducted in three ANC clinics in Kamwala, Chipata, and 
Chawama primary health centers in Lusaka urban district from 1 September 2014 through 
30 June 2015. Programmatic data indicate approximately 12,000 new ANC registrations are 
recorded annually in the three clinics. HIV prevalence ranges between 17 and 23% and RPR 
positivity for syphilis prevalence between 2 and 5%.The clinics are supported by the Centre 
for Infectious Disease Research in Zambia (CIDRZ) laboratory. CIDRZ is a 
nongovernmental organization-run laboratory serving public health services. They 
participate in external proficiency testing with One World Accuracy (Canada) and has met 
required scores (>80%) on the three cycles of External Quality Assessment (EQA) provided 
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annually since enrolment. This EQA is carried out for all tests done in the CIDRZ lab 
including HIV and syphilis.
Participant selection
Eligible participants were pregnant women ≥18 years presenting for first ANC visit who 
were able to provide informed consent. Recruitment was initiated through group health talks 
in ANC waiting areas. Following eligibility determination, interested women completed a 
consent form available in two local languages, Chinyanja and Bemba. For women with 
limited literacy, consent was read to them in their primary language in the presence of an 
impartial witness and thumbprint was used to obtain consent. All consenting participants 
completed an interviewer-administered questionnaire (SDC 6) and underwent clinical 
examination.
Sample size consideration
We estimated sample size based on an assumption of 17% HIV prevalence and 5% syphilis 
prevalence. We elected to use a more conservative syphilis prevalence estimate (5%) for the 
sample size calculation to account for different testing strategies in prior studies. Using 
precision approach to sample size calculation, 3765 pregnant women were required to 
evaluate the ability of each RDT to detect syphilis at 98% sensitivity with 2% precision at 
1.96 Z-score. During the course of the study, 1092 stored specimens were compromised and 
had to be discarded. These specimens were lost at random and not subject to any selection 
bias. To assess whether we had sufficient samples to complete the primary analysis, an 
interim analysis of the syphilis positivity rate in the study population was calculated. Based 
on a 9% syphilis positivity rate, it was determined that a sample size of 2100 was adequate 
to answer the primary outcome question under similar assumptions.
Data collection
We used structured questionnaires to collect participant data on sociodemographic 
characteristics including age of participant and gestational age, travel time to clinic, 
acceptability, and preferences for the dual tests (SDC 6). Study participants were 
interviewed by study staff following the testing procedure performed by the ANC staff to 
prevent bias. ANC staff performing the tests were interviewed on the feasibility of the dual 
RDTs (SDC 7).
Laboratory procedures
ANC clinic testing.—All participants were tested using both RDTs under evaluation in 
addition to standard of care testing. ANC nurses were trained prior to study initiation to 
perform the RDTs according to manufacturer’s instructions.10,11 Each result for a dual RDT 
was read two times. The first read at 15 min was read independently and blindly from the 
second read at 20 min.
An additional 5 ml of venous blood was collected in ethylenediaminetetraacetic acid 
anticoagulant tube, stored in cooler boxes, and sent for processing and reference testing at 
CIDRZ laboratory within 12 h of blood draw. These specimens were labeled with participant 
unique identifier, date, and time of collection.
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Reference laboratory testing. When received at the laboratory, specimens were logged into 
the Laboratory Information Management System. The blood was centrifuged and aliquoted 
into 2(1 ml) cryovials. HIV reference testing using RDTs was performed on plasma 
immediately upon arrival in the laboratory. The remaining plasma was frozen stored at 
−80°C for batch Treponema pallidum particle agglutination assay (TPPA) and rapid plasma 
reagin (RPR) testing, and if needed, repeat or future testing.
All reference tests were performed by technicians trained in the use of the assays for the 
study. The reference tests used for HIV were Determine (Alere Medical Company Limited, 
Japan) confirmed by Uni-Gold (Trinity Biotech, USA). The Western Blot (WB) (Biorad 
Laboratories) was available for use to resolve discordant results. The reference test used for 
syphilis was TPPA which is a treponemal test. Positive TPPA samples were then tested with 
RPR quantitative assays to determine whether the syphilis infection was active. For quality 
assurance purposes, positive and negative control runs were done daily with each batch of 
samples tested.
HIV samples nonreactive by Determine were considered negative; samples that were 
reactive by Determine were further tested using Uni-Gold. Samples with reactive results by 
both Determine and Uni-Gold were considered positive. Those samples with discordant 
results would have been further tested using WB; however, there were no discordant results.
Syphilis reference TPPA testing was conducted on batched frozen plasma at the end of the 
study. Samples with positive TPPA were further tested with the RPR quantitative test. 
Specimens with a positive TPPA test but a negative RPR were considered negative. Samples 
testing positive by both TPPA and RPR were considered to be probable active syphilis 
infections.
The details of the study procedures are depicted in online Figure 1 (SDC 1).
Statistical analysis
We assessed the diagnostic accuracy of the HIV and syphilis components separately 
(sensitivity and specificity) of each dual HIV/syphilis RDT against Determine (with Uni-
Gold confirmation) for HIV and TPPA for syphilis. Sensitivity was defined as the proportion 
of RDTs testing positive among those that tested positive based on reference testing. 
Specificity was defined as the proportion of RDTs testing negative among those that tested 
negative based on reference testing. In a subanalysis of syphilis diagnostic performance of 
the RDTs under study, we defined a separate reference standard for ‘active syphilis’ as all 
cases with TPPA positive and RPR positive with a titer of ≥1:4. A Kappa statistic was used 
to assess the agreement of test results.
We assessed acceptability of the two RDTs in the study population. Women were asked if 
they preferred single versus dual RDT testing (regardless of test brand) as well as their 
willingness to wait for test results. To assess the operational feasibility of the two RDTs, we 
calculated the mean score for all staff performing each test who responded to the 
questionnaire for each attribute (SDC 7). All analyses were performed using Stata MP 14 
(StataCorp, College Station, Texas, USA).
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Ethical considerations
All procedures were conducted in accordance with local standards of care. All participants 
provided informed consent before any procedures were conducted. This protocol and the 
informed consent documents were reviewed and approved by ethics committees responsible 
for oversight of the study, including (1) the WHO Research Project Review Panel and the 
WHO Research Ethics Review Committee, (2) the University of Zambia Biomedical 
Research Ethics Committee, and (3) the University of North Carolina at Chapel Hill 
Institutional Review Board.
Results
Characteristics of participants
We enrolled 3213 pregnant women across the three clinics of the total enrollment, 2121 
(66.0%) had blood samples available for the field performance of the tests analysis. Of the 
remaining 2121 participants, an additional two had missing laboratory results for the TPPA 
results (n = 2119 tests) and one had a missing laboratory result for the Determine HIV result 
(n = 2120) (Online Figure 2 - SDC 2),
The median age of pregnant women was 25 years (IQR = 21, 30) with median gestational 
age of 20 weeks (IQR = 16, 24). Over two-thirds (71%) of the participants were ≥20 weeks 
of gestation (Table 1).
The HIV prevalence in the study population was 19.2% (408/2120) and the syphilis 
prevalence was 9.7% (205/2119).
Diagnostic performance
When compared to reference testing, the HIV diagnostic performance of the Chembio RDT 
showed a sensitivity of 90.6% (95%CI = 87.4, 93.0) and a specificity of 97.2% (95%CI = 
96.2, 97.8). For the SD Bioline RDT the sensitivity was 89.4% (95%CI = 86.1, 92.0) and 
specificity was 96.3% (95%CI = 95.3, 97.1) (Table 2). The agreement of testing results as 
read by two testing conductors at 5 min apart was high and statistically significant: For the 
HIV component, the kappa statistic for Chembio was 0.98 and the kappa statistic for Bioline 
was 0.95 (Online Table 4 SDC 3).
The syphilis diagnostic performance of the Chembio RDT when compared to reference 
testing showed a sensitivity and specificity of 68.6% (95%CI = 61.9, 74.6) and 98.5% 
(95%CI = 97.8, 98.9), respectively. The SD Bioline RDT when compared to reference 
testing showed a sensitivity and specificity of 66.2% (95% CI = 59.4, 72.4) and 97.2% 
(95%CI = 96.4, 97.9), respectively.
When compared to an ‘active syphilis’ standard, RPR titers of 1:4 or greater, the sensitivity 
for detecting active syphilis was higher for both dual RDTs: 84.7% (95%CI = 76.1, 90.6) for 
Chembio and 81.6% (95% CI = 72.7, 88.1) (Table 3). Regarding the agreement of testing 
results as read by two conductors, the kappa statistic for syphilis was 0.96 for Chembio and 
0.91 SD Bioline (Online Table 4 SDC 3).
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Acceptability and feasibility of the RDTs
For acceptability, almost all the participants preferred the dual tests (99.7%) and were 
willing to wait for the results (99.9%) (Online Table 5 SDC 4). About two-thirds of 
participating women (64.3%) reported they would be willing to wait for up to 1 h.
For feasibility, the kits were rated by ANC nurses using a questionnaire (SDC 7) with the 
following mean scores: for Chembio = 20.0 (SD = 3.2); for SD Bioline = 20.1 (SD = 3.2) 
out of a maximum obtainable score of 25 (Online Table6 SDC 5).
Discussion
Findings of this field evaluation of the dual HIV/syphilis testing kits manufactured by 
Chembio Diagnostic Inc. and Standard Diagnostic Inc. showed similar performance as 
compared to other field-based studies.12–16 Acceptability and feasibility scores were high for 
both RDTs. This study is one of the few field evaluations contributing to data on the 
performance of the dual HIV/syphilis RDTs in field settings. These results can be considered 
to guide further evaluation and proposed scale up for use of RDTs in ANCs.
For HIV, compared to our laboratory-based reference, the sensitivity and specificity of the 
two RDTs were comparable. Results from other field evaluations of RDTs reported similar 
HIV sensitivity values of between 94 and 99%. The range for specificity of HIV diagnosis in 
these studies was 97–100% and comparable to results in this field evaluation.17
Compared to other field performance evaluations, our results for the syphilis component 
were also com-parable.14–16 Previously reported field-based evaluations have reported 
sensitivity ranging from 47 to 96% and specificity ranging from 91 to 100%.16,18 In our 
study, for syphilis, using the laboratory-based TPPA reference, sensitivity of the Chembio 
DPP was 69% and of the SD Bioline 66%. We also found in our subanalysis, which used 
syphilis RPR results ≥1:4 as indicative of more recent, or ‘active’, syphilis, the sensitivity of 
both kits was higher, at 84.7% Chembio and 81.6% SD Bioline, compared to using TPPA 
only. Other studies showed similar results in identifying active syphilis infection.15,16,18 This 
suggests a potential clinical advantage of using dual RDTs in ANCs where the imperative is 
identifying active syphilis that may affect the pregnancy rather than old, treated syphilis 
which might result in unnecessary treatment.
The results of our study are suggestive of what the performance of the RDTs might be 
outside of controlled laboratory settings. Laboratory environments are controlled settings 
where experienced, specially trained laboratory technologists conduct the tests and where 
serum rather than whole blood is used.19 Field conditions including poor lighting, limited 
space, high temperatures, and possible limited visual acuity of clinic staff conducting the 
tests may compromise results interpretation. In our study, ANC nurses were trained to 
conduct these tests prior to study initiation; however, they were also expected to conduct 
routine ANC testing. The ANC clinics are high volume and the staff-to-patient ratio is high 
without the extra task of performing multistep study-related testing. This would mimic the 
work conditions of the settings where the RDTs would be scaled up to increase HIV and 
syphilis screening coverage.
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In our study, the kits had high scores on reader reliability, acceptability, and feasibility which 
have also been shown in other published studies.16,18 Women reported preference for the 
dual HIV/syphilis RDTs as compared to single RDTs if available and were also willing to 
wait for the test results for up to 1 h. These results suggest that dual testing for HIV and 
syphilis is acceptable to participants and feasible for implementation in ANC settings. 
Incorporating dual test kits into routine ANC could potentially increase uptake of testing for 
HIV and syphilis among pregnant women and reduce the risk of MTCT.
This evaluation had some limitations. First, we used Determine with confirmation by Uni-
Gold as reference testing rather than the gold standard of EIA for HIV. Both are rapid tests, 
which may not reach the performance standard of laboratory-based HIV Enzyme 
Immunoassay (EIA) testing or allow for comparison of the Determine versus HIV EIA 
testing. Second, samples were frozen and were known to have undergone one to two freeze/
thaw cycles before completion of the reference testing for syphilis. The recommendation for 
the TPPA assay used is not more than one cycle. This may have impacted the performance 
accuracy for syphilis
Conclusions
Incorporating dual test kits into routine ANC could potentially increase uptake of testing and 
treatment for HIV and syphilis among pregnant women and reduce the risk of MTCT. The 
two dual RDTs evaluated in this study had comparable field performance for both HIV and 
syphilis when compared to other field evaluations. Both kits received high acceptability 
among pregnant women and were assessed as highly feasible by ANC nurses. These 
findings can be used to guide further research and proposed scale up in ANC settings.
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Table 1.
Characteristics of women enrolled into the study.
Characteristics
Number of pregnant
women N = 3213
Percent
of total
Age (years)
 Median (IQR) 25 (21, 30)
 18–19 454 14.1
 20–24 1146 35.7
 25–29 790 24.6
 30–34 527 16.4
 35–45 289 9
 Missing 7   0.2
Gestational age (weeks)
 Median (IQR) 20 (16, 24)
 <20 906 28.2
 20+ 2293 71.4
 Missing 14   0.4
Travel time (min)
 Median (IQR) 30 (20, 35)
 <30 min 1581 49.2
 30 min+ 1615 50.3
 Missing 17   0.5
Total 3213 100
IQR: interquartile range.
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Table 3.
Diagnostic accuracy for ‘active syphilis’a of dual HIV/ syphilis RDTs by brand of RDT in Lusaka, Zambia.
Comparison with active syphilisa
(combinations of TPPA and RPR)
Brand of RDT No. positive (sensitivity, %)
Chembio 98 (84.7)
SD Bioline 98 (81.6)
RDT: rapid diagnostic test; RPR: rapid plasma reagin; TPPA: Treponema pallidum particle agglutination assay.
aActive syphilis = TPPA positive and RPR ≥ 1:4 titer.
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